26
Participants
Start Date
March 30, 2017
Primary Completion Date
June 25, 2020
Study Completion Date
August 31, 2020
Aflibercept Ophthalmic
IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
optovue angiovue
FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
Stein Eye Institute of UCLA, Los Angeles
Regeneron Pharmaceuticals
INDUSTRY
University of California, Los Angeles
OTHER